

Probiomics Limited

ABN 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422

F: +61 2 9844 5445

W: www.probiomics.com.au

The Australian Stock Exchange Limited
Companies Announcements Office
SYDNEY

12 May 2009

Dear Sir/Madam

\$102,000 Private Placement

Probiomics Limited (PCC) is pleased to announce that Taylor Collision Limited has agreed to underwrite the placement of 17,000,000 shares to sophisticated investors at a price of \$0.006 per share. The placement is conditional upon conversion of at least \$ 450,000 of the face value of convertible notes into ordinary shares at \$0.01 and approval of all other resolutions at the General Meeting to be held on 15 May 2009.

The funds from the placement will be used for working capital.

Taylor Collision Limited will receive 6% commission on the funds raised and will be granted 2,500,000 options to purchase shares at \$ 0.02 with an expiry date of 5 years after issuance.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary
Tel: 02 9844 5422
Email ashok.jairath@probiomics.com.au

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.